Celgene Ltd

Morgan House, Madeira Walk, Windsor, Berkshire, SL4 1PE, UK
Telephone: +44 1753 498 600
Medical Information Direct Line: UK: 08448 010 045 Ireland: 1800 333 111
Medical Information e-mail: medinfo.uk.ire@celgene.com
Medical Information Fax: UK: 08448 010 046 Ireland: 1800 333 112
Summary of Product Characteristics last updated on the eMC: 04/11/2009
SPC Thalidomide Celgene 50 mg Hard Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/11/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC:   27-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Change of name from Thalidomide Pharmion 50mg Hard Capsules to Thalidomide Celgene 50mg Hard Capsules
Updated on 01/04/2009 and displayed until 04/11/2009
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   24-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

In section 4.2, peripheral neuropathy guidelines have been ammended.
Updated on 22/07/2008 and displayed until 01/04/2009
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

None provided

Active Ingredients/Generics

 
   thalidomide


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk